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EDITORIAL Open Access
Review and publication of protocol
submissions to Trials – what have we
learned in 10 years?
Tianjing Li1*, Isabelle Boutron2,3, Rustam Al-Shahi Salman4, Erik Cobo5, Ella Flemyng6, Jeremy M. Grimshaw7
and Douglas G. Altman8
Abstract
Trials has 10 years of experience in providing open access publication of protocols for randomised controlled trials.
In this editorial, the senior editors and editors-in-chief of Trials discuss editorial issues regarding managing trial
protocol submissions, including the content and format of the protocol, timing of submission, approaches to
tracking protocol amendments, and the purpose of peer reviewing a protocol submission. With the clarification and
guidance provided, we hope we can make the process of publishing trial protocols more efficient and useful to
trial investigators and readers.
The importance of establishing a protocol at the outset
of every clinical trial is unarguable [1–9]; however, the
availability and completeness of protocols and their
consistency with the final study report have been poor
[10–17]. Making protocols publicly available will con-
tribute to improving the transparency of research and
will enable researchers and prospective participants to
learn about trials that are underway. Protocol availability
also enables systematic reviewers, sponsors, regulators
and others to understand the scientific rigor of the de-
sign and results, as well as to compare what was
intended with what was described in the reports of trials
in order to assess possible reporting bias [7–20].
Journals and trial registries are part of the solution to
these problems because they provide a platform for mak-
ing trial protocols publicly available [8]. Beginning in
2006, Trials pioneered open access publication of proto-
cols for randomised controlled trials. Other journals have
taken similar approaches [21–23], but more than half of
published trial protocols have been published in Trials
[24]. From 2006 to November 2016, Trials published over
2100 protocols. In general, though at the editor’s discre-
tion, those protocols with previous full external peer
review as part of the process of receiving a grant from a
major external funding body or ethics approval were pub-
lished with peer review from a member of the editorial
board [25], with the remainder undergoing full peer re-
view. Trials provides authors with guidance [25], but
uncertainties remain.
The roles of journals, journal editors and peer re-
viewers are not well defined when a trial protocol, as a
stand-alone document, is submitted to a journal for con-
sideration for publication. How much detail should be
included in the protocol? What is the ‘right’ moment
that the protocol should be made publicly available?
How should subsequent protocol amendments be doc-
umented and linked to the published version of the
protocol? What are appropriate peer review and editor-
ial comments and suggestions when the trial is already
underway, especially if the protocol has already been
approved by the sponsor and the institutional review
board (IRB) or research ethics committee (REC)?
Herein we, the senior editors and editors-in-chief of
Trials, discuss editorial issues regarding managing pro-
tocols submitted for publication and provide guidance
for future protocol submissions to Trials.
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What is expected in a protocol submission?
Articles that describe protocols are different from
traditional trial ‘design articles’ and from the
Methods sections of articles that report trial results.
Design articles typically follow the format of a re-
search report, including Background, Methods,
Results and Discussion sections. We are aware of
two types of design articles. Design articles published
in clinical journals typically include an abbreviated
description of the protocol, are published after en-
rolment has been completed, and report baseline
characteristics of participants in the Results section.
Design articles published in methodological journals
focus on new, uncommon or challenging aspects of
the trial design or procedures; protocol details are
included only as necessary to understand the issues
[26]. Here readers can find examples of two design
articles, one for each type, arising from the same
trial [27, 28].
In contrast, a protocol, as defined in the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) statement, is
a document that provides sufficient detail to enable
understanding of the background, rationale, objectives,
study population, interventions, methods, statistical
analyses, ethical considerations, dissemination plans,
and administration of the trial; replication of key
aspects of trial methods and conduct; and appraisal
of the trial’s scientific and ethical rigour from ethics
approval to dissemination of results. ([29]; p. 203)
Typically, each element above is described in a distinct
section, and no performance or scientific results are
included.
So, a protocol should provide sufficient details for
readers to understand the general design and major op-
erating features of the trial. However, ‘this document is
generally distinguished from the study manual of opera-
tions by the absence of detailed instructions needed for
the actual application of treatment and data collection in
the trial’ [30]. Following the SPIRIT guideline is one way
to strike a balance between comprehensiveness and con-
ciseness [29, 31]. Trials endorses SPIRIT and requires
authors to submit a completed SPIRIT checklist as an
Appendix file and also to include a SPIRIT figure that
depicts the schedule of enrolment, interventions and
assessments within the main body of the article. The
Trials Editorial Office is asked to verify the fulfilment
of this requirement before assigning a new submission
to an editor.
When reviewing protocol submissions, we have no-
ticed that the completeness and understanding of the
reporting of items in the SPIRIT checklist could be
better among authors. In some submissions, the authors
have entered on the SPIRIT checklist ‘not applicable’ for
many critical items that in our view are applicable to
any randomised controlled trial (e.g., Item 6c. Explan-
ation for choice of comparators [29]). One possibility is
that what the item refers to was not done in the trial;
another is that the authors see the description as un-
necessary. When an item is truly ‘not applicable’, it is to
the authors’ advantage to provide a succinct explanation
so that the readers understand the rationale for not
addressing the item on the SPIRIT checklist in their
protocol. For items 16b and 16c concerning allocation
concealment mechanism and implementation [29], some
authors have mistakenly referred to the section of the
protocol that describes blinding. We encourage authors
to read the SPIRIT explanation and elaboration docu-
ment [31], which will help them improve their trial
design, save time in publishing the manuscript and en-
hance transparency. In addition, the items on the SPIRIT
checklist can be used as a general guide to organising
the contents of the protocol.
When to submit a protocol for publication
Procedures in trials almost always change over the
course of the trial for scientific and logistic reasons.
Some of these changes are trivial, such as modification
of an item on a data collection form to improve clarity,
but others might be important enough to trigger a
protocol amendment. For example, the IRB/REC, the
data monitoring committee or the sponsor may recom-
mend collecting safety outcomes that were unknown to
the investigators at the outset of the trial, adding a new
clinical site to achieve the target recruitment goal, or
adopting a new statistical method to analyse the data. In
general, protocol amendments should be limited to the
most relevant and critical ones that affect the trial design
and data collection procedure. The final version of the
protocol, which tracks all protocol amendments, pro-
vides a fuller and more accurate account of the trial
design and implementation than the version submitted
to the sponsor for funding, to the IRB/REC for ethics
approval, or to the data monitoring committee before
enrolment begins.
We encourage investigators to submit their trial
protocol for publication at an appropriate stage dur-
ing the conduct of the trial; almost always this
should be before recruitment is complete. In a ‘Trial
status’ section, the authors should report the proto-
col version number and date, the date on which re-
cruitment began, and the approximate date when
recruitment will be completed. Authors should also
describe any protocol amendments that were made
after trial commencement, along with the rationale
for such changes.
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When amendments are made to the protocol after its
publication in Trials, we encourage the authors to sub-
mit an ‘Update’, an article type that enables authors to
modify the published record. Depending on the particu-
lar amendments, the Update article is generally free to
submit and is linked back to the original article. Authors
should bear in mind that the credibility of a trial can be
damaged when changes are not reported, which also
complicates the assessment of a trial report at a later
date if inconsistencies between the protocol and the re-
port are identified.
As of November 2016, Trials had published 38 up-
dates, two-thirds of which are statistical analysis plans
(SAPs). We do not consider SAPs as protocol amend-
ments. A SAP describes the planned analysis for a clin-
ical trial. It may be written as a separate document
after finishing the protocol [32]. SAPs are required for
trials on regulated products, a subset of all trials. The
International Conference on Harmonisation defines a
SAP as ‘a document that contains a more technical and
detailed elaboration of the principal features of the
analysis described in the protocol, and includes
detailed procedures for executing the statistical analysis
of the primary and secondary variables and other data’
([32]; p. 35). At most pharmaceutical companies, the
trial statisticians write the SAP following a standar-
dised template; general guidance is under develop-
ment [33]. SAPs typically include sections providing a
brief description of the study design, a description of
the analysis population, data-handling rules, precise
analyses to be done and statistical methods to be
used for each, as well as shells for planned tables,
figures and listings [32]. We encourage trial investiga-
tors to submit SAPs, regardless of funding source,
and link them to the trial protocols when they
become available.
What is the purpose of peer review of trial
protocol submissions to Trials?
One essential purpose of peer review of a protocol
submission is to improve clarity of reporting. Because
the protocol is more than a list of items (e.g., as in
ClinicalTrials.gov or the World Health Organisation
International Clinical Trials Registry Platform), it is
reasonable for peer reviewers and editors to ask the
authors to provide a fuller and richer narrative of cer-
tain aspects of the design or, in some cases, to shorten
overly long descriptions, to clarify unclear and seem-
ingly inconsistent descriptions, and to provide justifi-
cations and rationales for aspects of the chosen
design.
The comments made by peer reviewers and editors
should be geared towards improving the reporting ra-
ther than commenting on the design. It is possible,
however, that the peer reviewers and editors may
raise concerns over the design. These suggestions, al-
though potentially valuable, are not typically within
the purview of a journal and usually cannot be imple-
mented by the investigators when the trial is already
underway. When appropriate, we may ask the authors
to discuss the issues and limitations raised by re-
viewers’ concerns. In addition, the readers of the final
results paper can consider these potential limitations
because the comments made by reviewers for Trials
are open to the public and published alongside the
article within the Open Peer Review reports. Finally,
the editors may invite a commentary on the design of
a trial or a set of trials.
Although our goal is to facilitate public availability of
trial protocols so that readers can judge the trials’ scien-
tific rigor, we reject some protocol submissions because
of a lack of clarify in reporting, poor adherence to
SPIRIT guidelines without justification, or serious con-
cerns over the design that preclude replication of the
trial by other researchers.
Can we improve the process?
The turnaround time for providing the authors with
the first decision on a protocol submission could be
shortened if (1) the authors optimised the quality of
reporting and submitted a manuscript that followed
the journal’s instructions and requirements, (2) the
editors and peer reviewers were familiar with the
journal’s position on the issues stated above, (3)
more of the trials community contributed to the
journal as editors and peer reviewers, and (4) peer
reviewers continued by providing constructive com-
ments intended to improve the quality of reporting.
Ultimately, Trials aims to increase value and reduce
waste in the reporting of clinical trials [7]. The prin-
cipal recommendations by Chan et al. for reducing
inaccessible research (see box below) illustrate the
value that investigators can derive from fully accessible
and clear reporting of clinical trial protocols [7], as well
as the role that Trials plays in facilitating this.
Box Recommendations from Chan et al. for reducing inaccessible
research in The Lancet’s Increasing Value, Reducing Waste series [7]
1. Institutions and funders should adopt performance metrics that
recognise full dissemination of research and reuse of original datasets
by external researchers
2. Investigators, funders, sponsors, regulators, research ethics
committees, and journals should systematically develop and adopt
standards for the content of study protocols and full study reports, and
for data sharing practices
3. Funders, sponsors, regulators, research ethics committees, journals,
and legislators should endorse and enforce study registration policies,
wide availability of full study information, and sharing of participant-level
data for all health research
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We encourage researchers to continue sending the
protocols for their randomised controlled trials to
Trials for consideration for publication. We also en-
courage researchers who are committed to full and
transparent reporting to join Trials as editors or
peer reviewers. We will strive to make the process
for publishing trial protocols more efficient and use-
ful to trial investigators and readers.
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